ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cipla to build plant in South Africa

by Jean-François Tremblay
July 18, 2016 | APPEARED IN VOLUME 94, ISSUE 29

The Indian generic drugs company Cipla will spend about $20 million to build a biosimilars plant in Durban, South Africa. Scheduled to come on-line in 2018, the plant, which will mostly produce cancer drugs, will employ about 300 people. Cipla says it hopes that its investment will help make biologic drugs affordable for 20% of the country’s patients, up from just 2% currently.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment